
Ark Therapeutics appoints new head of business development
pharmafile | June 12, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing |Â Â Ark Therapeutics, Bachem, Eden Biodesign, WatsonÂ
Ark Therapeutics has announced that Kassim Kolia has been appointed as head of business development.
In this role, Kolia will report directly to Dr David Venables, executive director – manufacturing services, with responsibility for building Ark’s manufacturing services business at its viral process development and manufacturing facility based in Kuopio, Finland.
Kolia joins Ark from Eden Biodesign, part of Watson Pharmaceuticals, where since 2006 he has been responsible for the business development of Eden Biodesign’s contract development and manufacturing services.
Prior to this Kolia was a key account manager at Bachem (UK) where he was responsible for business development of cGMP business opportunities for the company. Before the Bachem post Kolia held the role of cGMP line manager at Lonza Biologics, where he was responsible for the day-to-day running of the manufacturing plant.
Venables commented: “Kassim’s extensive experience in winning manufacturing service contracts will enable us to accelerate the development of our world-leading contract viral product development and manufacturing services capability into a major, self-sustaining business. I look forward to working with him at what is a very exciting time for Ark.”
Related Content
Pfizer teams up with IBM Watson Health in immuno-oncology
Pfizer and IBM Watson Health have announced a joint venture to accelerate research in immuno-oncology. …

Celgene partners with IBM for new pharmacovigilance platform
IBM is set to join forces with Celgene to develop a new drug safety evaluation …

Dendreon chief resigns from struggling firm
Chief executive of Dendreon John Johnson is to step down in the summer amid falling …






